Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
147.5 USD | +2.93% | +1.05% | -23.03% |
04-08 | Sector Update: Health Care Stocks Flat to Higher Premarket Monday | MT |
04-08 | Sector Update: Health Care | MT |
Evolution of the average Target Price on Alnylam Pharmaceuticals, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Alnylam Pharmaceuticals, Inc.
Chardan Research | |
Goldman Sachs | |
Wolfe Research | |
Morgan Stanley | |
JPMorgan Chase | |
RBC Capital Markets | |
Wells Fargo Securities | |
UBS | |
HC Wainwright | |
Oppenheimer | |
Bernstein | |
Evercore ISI | |
TD Cowen | |
BMO Capital | |
Citigroup | |
Needham & Co. | |
Raymond James | |
Canaccord Genuity | |
EF Hutton | |
SVB Securities LLC | |
Piper Sandler | |
Berenberg Bank | |
Jefferies & Co. | |
Cantor Fitzgerald | |
Guggenheim | |
William Blair & Co. | |
SVB Leerink | |
Stifel Nicolaus | |
Chardan | |
Barclays | |
Cowen |
EPS Revisions
- Stock Market
- Equities
- ALNY Stock
- Consensus Alnylam Pharmaceuticals, Inc.